Citigroup
VNDA icon

Citigroup’s Vanda Pharmaceuticals VNDA Stock Holding History

Citigroup’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-1,500
Closed -$14K – 7651
2020
Q3 		$14K Buy
1,500
+200
+15% +$2.14K ﹤0.01% 6426
2020
Q2 		$15K Sell
1,300
-2,300
-64% -$26K ﹤0.01% 6833
2020
Q1 		$37K Buy
3,600
+2,100
+140% +$26K ﹤0.01% 6252
2019
Q4 		$25K Buy
1,500
+1,300
+650% +$19.7K ﹤0.01% 6823
2019
Q3 		$3K Sell
200
-800
-80% -$11.1K ﹤0.01% 7488
2019
Q2 		$14K Sell
1,000
-300
-23% -$4.77K ﹤0.01% 7211
2019
Q1 		$24K Sell
1,300
-800
-38% -$18.2K ﹤0.01% 6864
2018
Q4 		$55K Sell
2,100
-2,000
-49% -$47K ﹤0.01% 6158
2018
Q3 		$94K Buy
4,100
+2,900
+242% +$59.2K ﹤0.01% 5972
2018
Q2 		$23K Sell
1,200
-7,100
-86% -$119K ﹤0.01% 6855
2018
Q1 		$140K Buy
8,300
+2,400
+41% +$40.2K ﹤0.01% 5304
2017
Q4 		$90K Sell
5,900
-4,900
-45% -$72.7K ﹤0.01% 5736
2017
Q3 		$193K Buy
10,800
+7,300
+209% +$122K ﹤0.01% 5022
2017
Q2 		$57K Sell
3,500
-2,800
-44% -$40.4K ﹤0.01% 5700
2017
Q1 		$88K Buy
6,300
+6,100
+3,050% +$86.9K ﹤0.01% 5302
2016
Q4 		$3K Sell
200
-3,700
-95% -$59.5K ﹤0.01% 7030
2016
Q3 		$65K Buy
3,900
+3,800
+3,800% +$51.2K ﹤0.01% 5489
2016
Q2 		$1K Sell
100
-1,100
-92% -$10.7K ﹤0.01% 7001
2016
Q1 		$10K Hold
1,200
– – ﹤0.01% 6807
2015
Q4 		$11K Sell
1,200
-300
-20% -$2.99K ﹤0.01% 6788
2015
Q3 		$17K Buy
1,500
+800
+114% +$9.79K ﹤0.01% 6152
2015
Q2 		$9K Buy
+700
New +$7.55K ﹤0.01% 6525

Other funds holding VNDA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citigroup's VNDA Position: Q2 2026 in Review

Citigroup reduced its Vanda Pharmaceuticals (VNDA) stake by 7.8% in Q2 2026, selling an estimated $45.7K and leaving 82,173 shares worth $503K. The position accounts for ﹤0.01% of the portfolio, ranked #3895.

Citigroup first reported a position in VNDA in Q2 2013 and has held it in 53 quarters since. The position peaked at $4.16M in Q2 2025. 172 funds tracked by Wall St. Rank hold VNDA as of Q2 2026.

  • Citigroup held 82,173 shares of Vanda Pharmaceuticals worth $503K as of Q2 2026.
  • Citigroup sold 6,991 Vanda Pharmaceuticals shares in Q2 2026, an estimated $45.7K.
  • Vanda Pharmaceuticals made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #3895 holding.
  • Citigroup first reported a position in Vanda Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
  • Citigroup's Vanda Pharmaceuticals position peaked at $4.16M in Q2 2025.
  • 172 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.